Literature DB >> 22736296

Incorporating information regarding preimplantation genetic diagnosis into discussions concerning testing and risk management for BRCA1/2 mutations: a qualitative study of patient preferences.

Karen Hurley1, Lisa R Rubin, Allison Werner-Lin, Michal Sagi, Yelena Kemel, Rikki Stern, Aliza Phillips, Ina Cholst, Noah Kauff, Kenneth Offit.   

Abstract

BACKGROUND: Studies have shown that BRCA1/2 mutation carriers are interested in learning about reproductive options such as preimplantation genetic diagnosis (PGD) to prevent passing their risk onto their children. However, attitudes vary widely, and the procedure raises complex ethical and psychosocial issues. This complexity, plus the highly technical nature of PGD, makes it difficult to integrate PGD information into genetic counseling sessions that already cover probabilistic, emotionally charged risk information.
METHODS: A total of 33 carriers of the BRCA1/2 mutation who were of reproductive age and had previously undergone genetic counseling viewed a tutorial regarding PGD and were interviewed concerning their attitudes toward PGD and preferences about how to include PGD information in genetic counseling.
RESULTS: The majority of participants preferred to be briefly informed of the availability of PGD information, and to receive written materials regarding PGD, but with the option of deferring detailed discussion if they already believed themselves to be overloaded or perceived that PGD was not immediately relevant to their risk management and/or childbearing plans. For some individuals, the stress of testing temporarily interfered with information processing, producing states of cognitive avoidance ("in a fog," or "tuning out"). Some preferred to discuss PGD with a physician with whom they had an ongoing relationship (eg, obstetrician/gynecologist, primary care provider, or oncologist).
CONCLUSIONS: Providers offering cancer genetic testing may consider indicating the availability of PGD information to their patients, while attending to the patients' level of interest and ability to absorb information. Research is needed to link patient responses to information overload with psychosocial outcomes (eg, distress, and quality of decision-making). Continuing medical education is needed to support providers in facilitating informed decisions regarding PGD.
Copyright © 2012 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22736296      PMCID: PMC4910088          DOI: 10.1002/cncr.27695

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  30 in total

Review 1.  Defense mechanisms in psychology today. Further processes for adaptation.

Authors:  P Cramer
Journal:  Am Psychol       Date:  2000-06

2.  Communication in genetic counseling: cognitive and emotional processing.

Authors:  Lee Ellington; Kimberly M Kelly; Maija Reblin; Seth Latimer; Debra Roter
Journal:  Health Commun       Date:  2011-06-09

3.  BRCA carriers' thoughts on risk management in relation to preimplantation genetic diagnosis and childbearing: when too many choices are just as difficult as none.

Authors:  Gwendolyn P Quinn; Susan T Vadaparampil; Sharon Tollin; Cheryl A Miree; Devin Murphy; Bethanne Bower; Celso Silva
Journal:  Fertil Steril       Date:  2010-05-05       Impact factor: 7.329

4.  Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996.

Authors: 
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

5.  Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians.

Authors:  L Wideroff; S T Vadaparampil; M H Greene; S Taplin; L Olson; A N Freedman
Journal:  J Med Genet       Date:  2005-03-22       Impact factor: 6.318

6.  High risk men's perceptions of pre-implantation genetic diagnosis for hereditary breast and ovarian cancer.

Authors:  Gwendolyn P Quinn; Susan T Vadaparampil; Cheryl A Miree; Ji-Hyun Lee; Xiuhua Zhao; Susan Friedman; Susan Yi; James Mayer
Journal:  Hum Reprod       Date:  2010-08-16       Impact factor: 6.918

7.  American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.

Authors: 
Journal:  J Clin Oncol       Date:  2003-04-11       Impact factor: 44.544

8.  Patients' need for information about cancer therapy.

Authors:  Karen A Skalla; Marie Bakitas; Charlotte T Furstenberg; Tim Ahles; Joseph V Henderson
Journal:  Oncol Nurs Forum       Date:  2004 Mar-Apr       Impact factor: 2.172

Review 9.  Psychosocial issues associated with genetic testing for breast and ovarian cancer risk: an integrative review.

Authors:  Jeannie V Pasacreta
Journal:  Cancer Invest       Date:  2003       Impact factor: 2.176

Review 10.  Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors.

Authors:  Janice L Berliner; Angela Musial Fay
Journal:  J Genet Couns       Date:  2007-05-17       Impact factor: 2.717

View more
  11 in total

1.  Performing and Declining PGD: Accounts of Jewish Israeli Women Who Carry a BRCA1/2 Mutation or Partners of Male Mutation Carriers.

Authors:  Efrat Dagan; Daphna Birenbaum-Carmeli; Eitan Friedman; Baruch Feldman
Journal:  J Genet Couns       Date:  2017-03-06       Impact factor: 2.537

2.  Uptake of Preimplantation Genetic Diagnosis in Female BRCA1 and BRCA2 Mutation Carriers.

Authors:  Pnina Mor; Sarah Brennenstuhl; Kelly A Metcalfe
Journal:  J Genet Couns       Date:  2018-06-01       Impact factor: 2.537

3.  Breast cancer, BRCA mutations, and attitudes regarding pregnancy and preimplantation genetic diagnosis.

Authors:  Ashley H Woodson; Kimberly I Muse; Heather Lin; Michelle Jackson; Danielle N Mattair; Leslie Schover; Terri Woodard; Laurie McKenzie; Richard L Theriault; Gabriel N Hortobágyi; Banu Arun; Susan K Peterson; Jessica Profato; Jennifer K Litton
Journal:  Oncologist       Date:  2014-06-20

4.  Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes.

Authors:  Thereasa A Rich; Mei Liu; Carol J Etzel; Sarah A Bannon; Maureen E Mork; Kaylene Ready; Devki S Saraiya; Elizabeth G Grubbs; Nancy D Perrier; Karen H Lu; Banu K Arun; Terri L Woodard; Leslie R Schover; Jennifer K Litton
Journal:  Fam Cancer       Date:  2014-06       Impact factor: 2.375

5.  Exome sequencing disclosures in pediatric cancer care: Patterns of communication among oncologists, genetic counselors, and parents.

Authors:  Sarah Scollon; Mary A Majumder; Katie Bergstrom; Tao Wang; Amy L McGuire; Jill O Robinson; Amanda M Gutierrez; Caroline H Lee; Susan G Hilsenbeck; Sharon E Plon; D Williams Parsons; Richard L Street
Journal:  Patient Educ Couns       Date:  2018-11-12

Review 6.  Management of genetic syndromes predisposing to gynecologic cancers.

Authors:  Susan Miesfeldt; Amanda Lamb; Christine Duarte
Journal:  Curr Treat Options Oncol       Date:  2013-03

7.  Breast cancer in the young: role of the geneticist.

Authors:  Ashley H Woodson; Jessica L Profato; Kimberly I Muse; Jennifer K Litton
Journal:  J Thorac Dis       Date:  2013-06       Impact factor: 2.895

8.  Positive association between lymphotoxin-alpha variation rs909253 and cancer risk: a meta-analysis based on 36 case-control studies.

Authors:  Xi Yu; Yi Huang; Changhong Li; Hailian Yang; Caide Lu; Shiwei Duan
Journal:  Tumour Biol       Date:  2013-10-18

9.  Patients' preimplantation genetic testing decision-making experience: an opinion on related psychological frameworks.

Authors:  L M Pastore; C N Cordeiro Mitchell; L R Rubin; J Nicoloro-SantaBarbara; M C Genoff Garzon; M Lobel
Journal:  Hum Reprod Open       Date:  2019-10-04

Review 10.  BRCA1/2 pathogenetic variant carriers and reproductive decisions: Gender differences and factors associated with the choice of preimplantation genetic diagnosis (PGD) and prenatal diagnosis (PND).

Authors:  Lucia Lombardi; Carmen Trumello; Liborio Stuppia; Ivana Antonucci; Tânia Brandão; Alessandra Babore
Journal:  J Assist Reprod Genet       Date:  2022-06-04       Impact factor: 3.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.